Runben Biotechnology Co Ltd. Class A

Runben Biotechnology Co Ltd. Class A

SSSE:603193
17.34
CNY
+0.40
(+2.36%)
0.86EPS
23.51P/E
8.19BMarket Cap
Mar 03Next Earn

Total Valuation

CNY

As of September 30, 2026, Runben Biotechnology Co Ltd. Class A carries a market capitalization of 8.19B, placing it among publicly traded companies globally. Its enterprise value stands at 6.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.19B
Enterprise Value6.75B

Important Dates

Runben Biotechnology Co Ltd. Class A's next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of September 30, 2026, Runben Biotechnology Co Ltd. Class A has 404.59M shares outstanding.

Shares Outstanding404.59M

Valuation Ratios

As of September 30, 2026, Runben Biotechnology Co Ltd. Class A trades at a trailing price-to-earnings ratio of 23.51. The price-to-sales ratio is 4.78, and the price-to-book ratio stands at 3.56.

PE Ratio23.51
PS Ratio4.78
PB Ratio3.56
P/TBV Ratio3.70

Enterprise Valuation

As of September 30, 2026, Runben Biotechnology Co Ltd. Class A trades at an EV/EBITDA multiple of 17.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.94 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.04 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.75B versus a market cap of 8.19B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.94
EV / EBITDA17.04
EV / EBIT17.04

Financial Position

As of September 30, 2026, Runben Biotechnology Co Ltd. Class A maintains a current ratio of 14.10, meaning it holds 14.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.02, indicating conservative leverage, while an interest coverage ratio of 9,368.04 demonstrates adequate ability to service its debt obligations.

Current Ratio14.10
Quick Ratio12.35
Debt / Equity0.02
Interest Coverage9,368.04

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Runben Biotechnology Co Ltd. Class A posted a return on equity (ROE) of 15.57, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.39 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.64, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 15.56, useful for judging operating efficiency across full business cycles. The company generates approximately 1.68M in revenue per employee across its workforce of 1,018.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.01 indicates how many times Runben Biotechnology Co Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)15.57
Return on Assets (ROA)14.64
Return on Invested Capital (ROIC)15.39
Return on Capital Employed (ROCE)15.56
Revenue Per Employee1.68M
Employee Count1,018.00
Inventory Turnover5.01

Taxes

CNY

Over the twelve months ended September 30, 2026, Runben Biotechnology Co Ltd. Class A recorded 46.97M in income tax expense. That works out to an effective tax rate of 11.88, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 395.52M, leaving 348.54M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax46.97M
Effective Tax Rate11.88

Stock Price Statistics

CNY

As of the close on November 17, 2026, Runben Biotechnology Co Ltd. Class A's stock has declined approximately 31.95% over the past 52 weeks. The 50-day moving average sits at 18.98, while the 200-day moving average is 21.50.

52-Week Price Change-31.95%
50-Day Moving Average18.98
200-Day Moving Average21.50

Income Statement

CNY

Over the twelve months ended September 30, 2026, Runben Biotechnology Co Ltd. Class A generated 1.71B in revenue and converted that into 348.54M in net income, yielding earnings per share of 0.86. EBITDA reached 396.06M, while operating income came in at 374.69M.

Revenue1.71B
Gross Profit1.03B
Operating Income374.69M
Pretax Income395.52M
Net Income348.54M
EBITDA396.06M
EBIT396.06M
Earnings Per Share (EPS)0.86

Balance Sheet

CNY

As of September 30, 2026, Runben Biotechnology Co Ltd. Class A holds 1.44B in cash and equivalents against 355,960.83 in total debt, resulting in a net debt position of -124.75M. Total book value stands at 2.30B, with working capital of 1.53B providing operational flexibility.

Cash & Cash Equivalents1.44B
Total Debt355,960.83
Net Debt-124.75M
Equity (Book Value)2.30B
Book Value Per Share5.69
Working Capital1.53B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-101.76M

Margins

Over the twelve months ended September 30, 2026, Runben Biotechnology Co Ltd. Class A posted a gross margin of 60.24, reflecting its pricing power and cost economics. The operating margin of 21.87 and net profit margin of 20.34 provide insight into operational efficiency.

Gross Margin60.24
Operating Margin21.87
Pretax Margin23.08
Profit Margin20.34
EBITDA Margin23.11

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Runben Biotechnology Co Ltd. Class A paid dividends of 0.29 per share. The dividend payout ratio of 33.18 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.66, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Runben Biotechnology Co Ltd. Class A shareholders.

Dividend Per Share0.29
Payout Ratio33.18
Shareholder Yield2.66

Scores

As of September 30, 2026, Runben Biotechnology Co Ltd. Class A has an Altman Z-Score of 43.39, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score43.39